Skip links
Orsini a specialty pharmacy partner for YORVIPATH® (palopegteriparatide), for hypoparathyroidism. Learn more →
Orsini now distributing BridgeBio's ATTRUBY™ (acoramidis), for ATTR-CM. Learn more →
Prescribe a Therapy
Orsini

← Back to Centers of Excellence

Cardiology Center of Excellence

Supporting patients living with a rare cardiology condition

Orsini’s Cardiology Center of Excellence launched in 2021 with our first program for homozygous familial hypercholesterolemia (HoFH). Today we support multiple cardiology programs across several rare conditions. Our dedicated Therapy Care Teams work with the physician’s office and insurance on a patient’s behalf so that our patients and their family have more time to focus on their treatment and quality of life. We are here to listen, provide counseling on treatment, including side-effect management, and assist with sourcing third-party financial assistance.

Explore Our Cardiology Therapies

Benefits

Improving the Patient Experience, Every Time

Dedicated Care Team

Receive personalized support from a dedicated Therapy Care Team, including a primary pharmacy contact, clinical education, side-effects management, and scheduled refill calls.

Home Health Nursing

Access nationwide nursing support for in-home treatment or self-administration training. Our nurses provide clinical support to help patients achieve their treatment goals.

Insurance Coverage

Secure treatment coverage with assistance navigating payor and plan requirements. Our team proactively works with prescribers to obtain prior authorization and support appeals.

Free Care Overnight Shipping

Ensure medication and essential medical supplies arrive when and where patients need them through coordination across prescribers, patients, and care teams to arrange free overnight shipping.

Financial Assistance

Minimize financial exposure through financial assistance programs. We successfully identify and assist in enrolling patients into manufacturer co-pay and foundation support programs.

24/7/365 Access to a Pharmacist

Gain continuous access to a pharmacist, 24/7/365, ensuring ongoing care and clinical support for patients and prescribers to achieve better outcomes.

Support

Cardiology Conditions Supported

Explore the rare cardiology conditions and therapies Orsini supports below.

About Cryopyrin-Associated Periodic Syndromes (CAPS)

Cryopyrin-associated periodic syndromes are a group of rare, hereditary autoinflammatory disorders. They are inherited in an autosomal dominant pattern, which means that a mutation in 1 copy of the gene is enough to cause the disorder. CAPS are characterized by lifelong recurrent symptoms of rash, fever/chills, joint pain, eye redness/pain, and fatigue. The estimated incidence in the United States is 1 to 2 cases per million people.

CAPS Therapies Supported

Full Name Arcalyst® (rilonacept)
Drug Arcalyst
Manufacturer Kiniksa Pharmaceuticals (UK), Ltd.
Route of Administration Subcutaneous
Site of Care Home
Approved Indication Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS), and Muckle-Wells Syndrome (MWS) in adults and children 12 years and older; maintenance of remission of Deficiency of Interleukin-1 Receptor Antagonist (DIRA) in adults and pediatric patients weighing 10 kg or more; and treatment of recurrent pericarditis (RP) and reduction in risk of recurrence in adults and children 12 years and older
Disease Cryopyrin-Associated Periodic Syndromes (CAPS); Deficiency of Interleukin-1 Receptor Antagonist (DIRA); Recurrent Pericarditis (RP)
Therapeutic Area Cardiology
Enrollment Form Link Enrollment Form
Phone Number 800-473-3261
Fax Number 877-576-6745
Product Website arcalyst.com/hcp

About Deficiency of Interleukin-1 Receptor Antagonist (DIRA)

Deficiency of interleukin-1 receptor antagonist (DIRA) is an autoinflammatory disease first reported in 2009 that is characterized by the absence of functional interleukin-1 receptor antagonist (IL-1Ra) protein. Patients with DIRA have life-threatening systemic inflammation with skin and bone involvement. DIRA is a genetic disorder inherited in an autosomal recessive manner, meaning that a mutation in both copies of a gene is needed to cause the disease. DIRA is a very rare disease, with fewer than 50 patients worldwide.

DIRA Therapies Supported

Full Name Arcalyst® (rilonacept)
Drug Arcalyst
Manufacturer Kiniksa Pharmaceuticals (UK), Ltd.
Route of Administration Subcutaneous
Site of Care Home
Approved Indication Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS), and Muckle-Wells Syndrome (MWS) in adults and children 12 years and older; maintenance of remission of Deficiency of Interleukin-1 Receptor Antagonist (DIRA) in adults and pediatric patients weighing 10 kg or more; and treatment of recurrent pericarditis (RP) and reduction in risk of recurrence in adults and children 12 years and older
Disease Cryopyrin-Associated Periodic Syndromes (CAPS); Deficiency of Interleukin-1 Receptor Antagonist (DIRA); Recurrent Pericarditis (RP)
Therapeutic Area Cardiology
Enrollment Form Link Enrollment Form
Phone Number 800-473-3261
Fax Number 877-576-6745
Product Website arcalyst.com/hcp

About Heart Failure

Heart failure, also called congestive heart failure, occurs when the heart no longer pumps enough blood for the body’s needs, sometimes because the heart can’t fill up with enough blood and other times due to weakness of the heart. There are more than 7 million people with heart failure in the United States, and many are prone to hospitalization for congestion as they have become resistant to oral diuretics

Heart Failure Therapies Supported

Full Name FUROSCIX® (furosemide injection) 80 mg/10 mL for subcutaneous use
Drug Furosemide
Manufacturer scPharmaceuticals Inc.
Route of Administration Subcutaneous
Site of Care Home
Approved Indication FUROSCIX is indicated for the treatment of congestion due to fluid overload in adults with chronic heart failure. Please see the full Prescribing Information and Instructions for Use.
Disease Heart Failure
Therapeutic Area Cardiology
Enrollment Form Link www.furoscix.com/hcp/contact-us
Phone Number 855-387-6724
Product Website www.furoscix.com/hcp/

About Heterozygous Familial Hypercholesterolemia (HeFH)

Heterozygous familial hypercholesterolemia is an inherited genetic disorder characterized by elevated levels of LDL (“bad”) cholesterol from birth. Unlike the more severe homozygous form, individuals with HeFH have one affected gene, leading to high cholesterol levels and an increased risk of premature cardiovascular disease. Symptoms may include cholesterol deposits in tendons and a family history of early heart disease.

HeFH Therapies Supported

Drug Name Leqvio® (inclisiran)
Manufacturer Novartis Pharmaceuticals
Route of Administration Subcutaneous
Approved Indication The treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD), who require additional lowering of low-density lipoprotein cholesterol (LDL-C)
Disease Primary Hyperlipidemia; Heterozygous Familial Hypercholesterolemia (HeFH)
Therapeutic Area Cardiology
Enrollment Form Link Enrollment Form
Phone Numbers 800-372-6153 (Enrollment), 877-515-9670 (Support)
Product Website leqvio.com

About Homozygous Familial Hypercholesterolemia (HoFH)

Homozygous familial hypercholesterolemia is an ultra-rare, inherited genetic disorder causing extremely high levels of cholesterol in the blood. It affects approximately 1,300 patients in the U.S. Individuals with HoFH have impaired ability to remove LDL (“bad”) cholesterol, leading to severe and premature cardiovascular issues. This condition is more aggressive than typical familial hypercholesterolemia. Symptoms may include early-onset heart disease and cholesterol deposits in tendons.

HoFH Therapies Supported

Full Name Evkeeza® (evinacumab-dgnb)
Drug Evkeeza
Manufacturer Regeneron Pharmaceuticals
Route of Administration Intravenous
Site of Care Home or Healthcare Facility
Approved Indication Adjunct to other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients, aged 12 years and older, with homozygous familial hypercholesterolemia (HoFH)
Disease Homozygous Familial Hypercholesterolemia (HoFH)
Therapeutic Area Cardiology
Enrollment Form Link Enrollment Form
Phone Number 800-645-4142
Fax Number 877-473-0199
Product Website evkeezahcp.com

About Primary Hyperlipidemia

Primary hyperlipidemia is a metabolic disorder characterized by elevated levels of cholesterol and/or triglycerides in the blood, primarily due to genetic factors. This condition disrupts the normal balance of fats, contributing to atherosclerosis and cardiovascular complications. Individuals with Primary Hyperlipidemia may experience no noticeable symptoms, emphasizing the importance of regular lipid screenings for early detection.

Primary Hyperlipidemia Therapies Supported

Drug Name Leqvio® (inclisiran)
Manufacturer Novartis Pharmaceuticals
Route of Administration Subcutaneous
Approved Indication The treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD), who require additional lowering of low-density lipoprotein cholesterol (LDL-C)
Disease Primary Hyperlipidemia; Heterozygous Familial Hypercholesterolemia (HeFH)
Therapeutic Area Cardiology
Enrollment Form Link Enrollment Form
Phone Numbers 800-372-6153 (Enrollment), 877-515-9670 (Support)
Product Website leqvio.com

About Recurrent Pericarditis (RP)

Recurrent pericarditis is a painful autoinflammatory cardiovascular disease that occurs when patients with acute pericarditis experience one or more pericarditis episodes after being symptom-free for 4-6 weeks. The symptoms associated with RP affect patients’ quality of life, can limit physical activities, and lead to frequent emergency department visits and hospitalizations. RP can affect people of all ages and ethnicities, and it is estimated that 40,000 patients in the US seek treatment annually for RP.

RP Therapies Supported

Full Name Arcalyst® (rilonacept)
Drug Arcalyst
Manufacturer Kiniksa Pharmaceuticals (UK), Ltd.
Route of Administration Subcutaneous
Site of Care Home
Approved Indication Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS), and Muckle-Wells Syndrome (MWS) in adults and children 12 years and older; maintenance of remission of Deficiency of Interleukin-1 Receptor Antagonist (DIRA) in adults and pediatric patients weighing 10 kg or more; and treatment of recurrent pericarditis (RP) and reduction in risk of recurrence in adults and children 12 years and older
Disease Cryopyrin-Associated Periodic Syndromes (CAPS); Deficiency of Interleukin-1 Receptor Antagonist (DIRA); Recurrent Pericarditis (RP)
Therapeutic Area Cardiology
Enrollment Form Link Enrollment Form
Phone Number 800-473-3261
Fax Number 877-576-6745
Product Website arcalyst.com/hcp

About Transthyretin-mediated amyloidosis – Cardiomyopathy (ATTR-CM)

Cardiomyopathy of transthyretin-mediated amyloidosis is a disorder leading to abnormal protein buildup, forming amyloids that accumulate in the heart. This rare condition affects the heart’s structure and function, causing cardiomyopathy. Symptoms include fatigue, shortness of breath, and heart-related issues. As an inherited disorder, it often runs in families. Amyloid deposits can also affect the functioning of the heart, kidneys, eyes, and gastrointestinal tract.

ATTR-CM Therapies Supported

Full Name ATTRUBY™ (acoramidis)
Drug Acoramidis
Manufacturer BridgeBio Pharma, Inc.
Route of Administration Oral
Site of Care Home
Approved Indication ATTRUBY is a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization. Please see the full Prescribing Information.
Disease Cardiomyopathy of transthyretin-mediated amyloidosis (ATTR-CM)
Therapeutic Area Cardiology
Enrollment Form Link Enrollment Form
Phone Number 888-331-6574
Fax Number 877-349-1473
Product Website www.attruby.com

Full Name Vyndamax® (tafamidis)
Drug Vyndamax
Manufacturer Pfizer
Route of Administration Oral
Site of Care Home
Approved Indication The treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization
Disease Hereditary ATTR amyloidosis (hATTR) - Cardiomyopathy (CM); Wild type transthyretin amyloid cardiomyopathy (wtATTR-CM)
Therapeutic Area Cardiology
Enrollment Form Link Vyndamax Enrollment Form
Phone Number 800-930-2043
Fax Number 877-684-3116
Product Website vyndamax.pfizerpro.com

Full Name Vyndaqel® (tafamidis meglumine)
Drug Vyndaqel
Manufacturer Pfizer
Route of Administration Oral
Site of Care Home
Approved Indication The treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization
Disease Hereditary ATTR amyloidosis (hATTR) - Cardiomyopathy (CM); Wild type transthyretin amyloid cardiomyopathy (wtATTR-CM)
Therapeutic Area Cardiology
Enrollment Form Link Vyndaqel Enrollment Form
Phone Number 800-930-2043
Fax Number 877-684-3116
Product Website vyndamax.pfizerpro.com